Cassava Sciences Inc (NASDAQ:SAVA)
| 29.88 Delayed Data As of 3:59pm ET |  +0.29 / +0.98%Today’s Change | 13.84 Today|||52-Week Range 62.49 | +1.15% Year-to-Date |
Latest SAVA News | Press Releases
| 3 Big Reasons to Sell Cassava Sciences Stock Right Now Feb 01 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 29.59 |
| Today’s open | 29.51 |
| Day’s range | 28.53 - 30.18 |
| Volume | 18,948 |
| Average volume (3 months) | 1,550,407 |
| Market cap | $1.3B |
Data as of 3:59pm ET, 02/07/2023
Growth & Valuation
| Earnings growth (last year) | -238.75% |
| Earnings growth (this year) | -142.28% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 4.87 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| GERNGeron Corp | -0.04 | -1.08% |
| DCPHDeciphera Pharmaceut... | -0.13 | -0.78% |
| AUPHAurinia Pharmaceutic... | -0.13 | -1.43% |
| IOVAIovance Biotherapeut... | 0.00 | 0.00% |
Data as of 4:00pm ET, 02/07/2023
Financials
| Next reporting date | March 29, 2023 |
| EPS forecast (this quarter) | -$0.56 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$32.4M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Austin, Texas |
Forecasts
